Research programme: chronic myelogenous leukaemia therapeutics - Novartis/SGX Pharmaceuticals

Drug Profile

Research programme: chronic myelogenous leukaemia therapeutics - Novartis/SGX Pharmaceuticals

Alternative Names: 7-Azaindole inhibitors; SGX 393; SGX 70393; SGX-70430

Latest Information Update: 19 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SGX Pharmaceuticals
  • Developer Novartis; SGX Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chronic myeloid leukaemia

Most Recent Events

  • 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly
  • 30 Jun 2008 SGX Pharmaceuticals files an IND application with the US FDA for SGX 393
  • 11 Dec 2007 Pharmacodynamics data from a preclinical trial presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top